胰高血糖素和GLP-1受体双重激动剂survodutide治疗肥胖:一项随机、双盲、安慰剂对照、剂量探索2期试验
这项在12国43中心开展的随机双盲安慰剂对照2期试验纳入387例无糖尿病肥胖者,按1:1:1:1:1随机接受survodutide 0.6、2.4、3.6、4.8 mg或安慰剂每周皮下注射46周。按计划治疗分析,第46周体重较基线平均变化分别为-6.2%、-12.5%、-13.2%、-14.9%和-2.8%。所有剂量均耐受,体重呈剂量依赖性下降。
要点
- survodutide各剂量组体重降幅均大于安慰剂,且呈剂量依赖性。
- 4.8 mg组体重平均变化-14.9%(95%CI -16.9至-13.0)。
- 不良事件主要为胃肠道反应,survodutide组75% vs 安慰剂组42%。
核心结论
- 所有测试剂量的survodutide均耐受,并呈剂量依赖性降低体重。
研究设计与样本
- 随机、双盲、安慰剂对照、剂量探索2期试验,在12个国家43个中心开展。
- 纳入387例年龄18-75岁、BMI≥27 kg/m2、无糖尿病的参与者,按1:1:1:1:1随机分配(按性别分层)接受survodutide 0.6、2.4、3.6、4.8 mg或安慰剂每周皮下注射46周(20周剂量递增;26周剂量维持)。
- 主要终点为基线至第46周体重百分比变化;主要分析基于改良意向治疗人群(至少接受一剂试验药物且至少一个疗效终点可分析),按随机分配剂量分析,并将COVID-19相关中断数据删失。
- 敏感性分析基于维持期实际接受剂量(实际治疗)并纳入治疗中数据;安全性分析纳入所有至少接受一剂研究药物的参与者。
- 试验注册于ClinicalTrials.gov(NCT04667377)和EudraCT(2020-002479-37)。
主要发现
- 2021年3月30日至2021年11月11日纳入387例参与者;386例(100%)接受治疗(0.6 mg组n=77;2.4 mg组n=78;3.6 mg组n=77;4.8 mg组n=77;安慰剂组n=77)。
- 386例中233例(60.4%)完成46周治疗期(survodutide组309例中187例[61%];安慰剂组77例中46例[60%])。
- 按计划治疗分析,基线至第46周体重平均变化(95%CI)为:0.6 mg组-6.2%(-8.3至-4.1);2.4 mg组-12.5%(-14.5至-10.5);3.6 mg组-13.2%(-15.3至-11.2);4.8 mg组-14.9%(-16.9至-13.0);安慰剂组-2.8%(-4.9至-0.7)。
- 不良事件发生于survodutide组309例中281例(91%)和安慰剂组77例中58例(75%);主要为胃肠道不良事件,survodutide组309例中232例(75%)和安慰剂组77例中32例(42%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obesity is a widespread and chronic condition that requires long-term management; research into additional targets to improve treatment outcomes remains a priority. This study aimed to investigate the safety, tolerability, and efficacy of glucagon receptor-GLP-1 receptor dual agonist survodutide (BI 456906) in obesity management. METHODS: In this randomised, double-blind, placebo-controlled, dose-finding phase 2 trial conducted in 43 centres in 12 countries, we enrolled participants (aged 18-75 years, BMI ≥27 kg/m2, without diabetes) and randomly assigned them by interactive response technology (1:1:1:1:1; stratified by sex) to subcutaneous survodutide (0·6, 2·4, 3·6, or 4·8 mg) or placebo once-weekly for 46 weeks (20 weeks dose escalation; 26 weeks dose maintenance). The primary endpoint was the percentage change in bodyweight from baseline to week 46. Primary analysis included the modified intention-to-treat population (defined as all randomly assigned patients who received at least one dose of trial medication and who had analysable data for at least one efficacy endpoint) and was based on the dose assigned at randomisation (planned treatment), including all data censored for COVID-19-related discontinuations; the sensitivity analysis was based on the actual dose received during maintenance phase (actual treatment) and included on-treatment data. Safety analysis included all participants who received at least one dose of study drug. The trial is registered with ClinicalTrials.gov (NCT04667377) and EudraCT (2020-002479-37). FINDINGS: Between March 30, 2021, and Nov 11, 2021, we enrolled 387 participants; 386 (100%) participants were treated (0·6 mg, n=77; 2·4 mg, n=78; 3·6 mg, n=77; 4·8 mg, n=77; placebo n=77) and 233 (60·4%) of 386 completed the 46-week treatment period (187 [61%] of 309 receiving survodutide; 46 [60%] of 77 receiving placebo). When analysed according to planned treatment, mean (95% CI) changes in bodyweight from baseline to week 46 were -6·2% (-8·3 to -4·1; 0·6 mg); -12·5% (-14·5 to -10·5; 2·4 mg); -13·2% (-15·3 to -11·2; 3·6 mg); -14·9% (-16·9 to -13·0; 4·8 mg); -2·8% (-4·9 to -0·7; placebo). Adverse events occurred in 281 (91%) of 309 survodutide recipients and 58 (75%) of 77 placebo recipients; these were primarily gastrointestinal in 232 (75%) of 309 survodutide recipients and 32 (42%) of 77 placebo recipients. INTERPRETATION: All tested survodutide doses were tolerated, and dose-dependently reduced bodyweight. FUNDING: Boehringer Ingelheim.
引用
- le Roux CW, Steen O, Lucas KJ, et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024. PMID: 38330987. doi:10.1016/S2213-8587(23)00356-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。